Adam J. Eqbal

Adam J. Eqbal

Auto-generated profile, based on publicly available information

Adam J. Eqbal

Division of Cardiac Surgery McMaster University Ontario Hamilton Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
AEAdam J. Eqbal
Adam J. Eqbal
SGSaurabh Gupta
Saurabh Gupta
ABAmeen Basha
Ameen Basha
YQYuan Qiu
Yuan Qiu
NWNicole Wu
Nicole Wu
RWRichard P. Whitlock
Richard P. Whitlock

16 May 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
AEAdam Eqbal
Adam Eqbal
WTWesley Tong
Wesley Tong
ALAndre Lamy
Andre Lamy
EBEmilie Belley-Côté
Emilie Belley-Côté
DPDomenico Paparella
Domenico Paparella
TIthe LAAOS III Investigators
the LAAOS III Investigators
Background: The LAAOS III (Left Atrial Appendage Occlusion Study) clinical trial demonstrated that concomitant left atrial appendage (LAA) occlusion leads to a lower risk of ischemic stroke or systemic embolism compared with no occlusion in participants with atrial fibrillation and a CHA 2 DS 2 ‐VASc score of ≥2 undergoing cardiac surgery for another indication. We report the cost implications of concomitant LAA occlusion during cardiac surgery. Methods and Results: Using LAAOS III data, we compared the costs (in US dollars) associated with LAA occlusion to no occlusion from the perspective of the Centers for Medicare and Medicaid Services. We calculated the average cost per participant during the trial by applying Medicare reimbursement costs to cardiovascular events for all trial participants. We conducted sensitivity analyses, varying the cost of stroke ±25% and occlusion technique use. Cost neutrality was defined as a mean cost difference within ±5% of the cost per participant in the no‐occlusion group. Total study cost per participant was $3878 in the LAA occlusion group and $4490 in the no‐occlusion group, a mean difference of −$612 (95% CI, −$1276 to $45). The main drivers of cost savings were fewer stroke events during the trial (mean difference of −$1021). In sensitivity analyses, LAA occlusion was cost saving for suture and stapler techniques but more expensive with closure device. Conclusions: Concomitant LAA occlusion was cost saving for participants in LAAOS III. Our findings support concomitant LAA occlusion as an economically dominant strategy for patients with atrial fibrillation and a CHA 2 DS 2 ‐VASc score of ≥2 undergoing cardiac surgery.

17 August 2022 in JACC: Case Reports
Verified
Journal Article
Open access
AEAdam J. Eqbal
Adam J. Eqbal
LGLaura Goodliffe
Laura Goodliffe
HMHassan Masoom
Hassan Masoom
MAMuhammad Ajlan
Muhammad Ajlan
JHJessica Hanna
Jessica Hanna
RWRichard P. Whitlock
Richard P. Whitlock
Primary cardiac synovial sarcomas are very rare, representing <1% of all primary cardiac tumors. We report the case of a 19-year-old man with syncope and dynamic obstructive shock caused by a large right-sided intracardiac tumor. (Level of Difficulty: Beginner .)